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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the 
most common subtype of non-Hodgkin lymphoma, and 
addition of rituximab to cyclophosphamide, doxorubicin, 
vincristine, and prednisone chemotherapy (R-CHOP) 
has improved the outcome of patients with DLBCL [1]. 
Although several reports suggest that incorporation of 
rituximab decreased the rate of central nervous system 
(CNS) relapse [2, 3], the use of rituximab has failed to 
decrease the incidence of CNS involvement in patients 
with an age-adjusted International Prognostic Index (IPI) 
≥ 2 [4], and clinical outcomes of those patients are still 
poor in the rituximab era [5–8]. 
Traditionally, the involvement of certain extranodal 
sites or nodal lesion such as retroperitoneal lymph nodes 
is known to confer a higher risk of CNS involvement [6, 
9–12]. Some parameters that reflect the tumor burden, 
including serum lactate dehydrogenase (LDH) and the 
number of involved extranodal sites were associated with the 
risk of CNS relapse in previous studies [2, 10]. However, a 
majority of the studies were retrospective analyses and there 
is heterogeneity of some crucial factors, such as definition 
of CNS relapse, methods for CNS evaluation, and whether 
doing CNS prophylaxis or not. Recently, German High-
Grade Non-Hodgkin Lymphoma Study Group proposed 
a risk model for the prediction of CNS relapse among 
patients with DLBCL treated with rituximab-containing 
immunochemotherapy [13]. They defined five conventional 
IPI factors in addition to involvement of kidney or adrenal 
gland as factors for CNS relapse (CNS-IPI). The CNS-
IPI effectively stratified 2,164 DLBCL patients into 3 risk 
groups according to the rate of CNS relapse at 2 years. The 
model was successfully validated among 1,597 patients 
from the British Columbia Cancer Agency [13]. 
In DLBCL, the National Comprehensive Cancer 
Network (NCCN)-IPI showed better prognostication 
compared to existing standard IPI [14]. Therefore, it would 
be interesting to evaluate whether enhanced stratification 
of age or serum LDH contributes to better prediction for 
CNS relapse. In addition, there has been a scarce of large 
study regarding CNS relapse of DLBCL among Asian 
population. Thus, we conducted a multicenter prospective 
cohort study to evaluate the incidence and risk factors for 
CNS involvement in patients with DLBCL treated with 
R-CHOP immunochemotherapy.
RESULTS
Patients and overall treatment outcomes
From August 2010 to August 2012, 603 patients 
were enrolled. Eight patients were excluded because four 
patients had withdrawn their consent and the other four 
patients did not meet the inclusion criteria: three patients 
did not have DLBCL after pathology review, and one 
patient could not receive R-CHOP due to liver cirrhosis. 
Thus, the data for 595 patients were finally analyzed, and 
their median age was 60 years (range: 20– 89). Baseline 
characteristics of patients were summarized in Table 1. The 
median cycle number of R-CHOP was six (range: 1–8), and 
the overall response rate was 90% (534/595) including 480 
patients (81%) with a complete response (CR) and 54 (9%) 
with a partial response. The remaining 61 patients included 
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those with stable disease (n = 3), disease progression during 
treatment (n = 38), and an undetermined response (n = 20). 
The reason for an undetermined response was that the 
patient discontinued treatment after the first or second cycle 
of R-CHOP due to treatment-related toxicity. At the time 
of analysis, 164 patients experienced disease progression 
or relapse, and 141 patients died from the disease (n = 
93) or other causes (n = 48). During the median follow-
up duration of 35.0 months [95% confidence interval (CI), 
34.2–35.8 months], the 3-year progression-free survival 
(PFS) and overall survival (OS) were 72% (95% CI, 68.8–
75.8) and 75.8% (95% CI, 72.3–79.3), respectively.
CNS involvement
CNS evaluation was performed in 279 patients who 
had suspicious symptom or sign for CNS involvement 
or had ≥ 1 risk factors according to the recommendation 
of the protocol. Fourteen patients had CNS involvement 
(2.4% out of entire patients and 5.0% out of 279 
patients with baseline CNS evaluation; Figure 1). 
This involvement included the presence of lymphoma 
cells in the cerebrospinal fluid (CSF) (n = 9) and brain 
parenchymal lesions (n = 5). All of them received CNS-
directed therapy together with R-CHOP except one patient 
who died of infection during the first cycle of R-CHOP. 
During the follow-up, 26 patients underwent CNS relapse. 
Nineteen of them underwent isolated CNS relapse and 7 
patients had synchronous CNS and systemic relapse. The 
1-year and 2-year rate of CNS relapse was 3.2% (95% 
CI, 1.6–4.8) and 4.7% (95% CI, 2.9–6.4%), respectively. 
Among 265 patients who were initially negative for CNS 
evaluation, 18 patients (6.9%) had CNS relapse whereas 
8 cases (2.5%) of CNS involvement occurred in 316 
patients who were not evaluated at diagnosis (Figure 
1). Of those 26 patients with CNS relapse, 16 and 24 
Table 1: Characteristics of patients
All patients Without CNS involvement
(n = 595) At diagnosis (n = 581)
Characteristic n % n %
Sex Male 340 57 332 57
Age ≤ 40 years 71 12 70 12
41–60 years 240 40 234 40
61–75 years 214 36 208 36
> 75 years 70 12 69 12
Performance status ECOG ≥ 2 70 12 68 12
Ann Arbor stage III/IV 301 51 287 49
Serum LDH Not increased 308 52 303 52
× 1~3 ULN 246 41 239 41
> ×3 ULN 41 7 39 7
extranodal sites (No. ≥ 2 207 35 196 33
Standard IPI (score) Low (0–1) 265 45 262 45
Low-intermediate (2) 120 20 118 20
High-intermediate (3) 112 19 108 19
High (4–5) 98 16 93 16
NCCN-IPI (score) Low (0–1) 102 17 102 18
Low-intermediate (2–3) 280 47 276 47
High-intermediate (4–5) 164 28 155 27
High (≥ 6) 49 8 48 8
B symptoms Presence 145 24 141 24
Serum albumin < 3.5 g/dL 135 23 129 22
Hemoglobin < 10 g/dL 83 14 81 14
Platelet count < 100,000/mm3 34 6 33 6
Lymphocyte count < 1,000/mm3 141 24 137 24
ECOG, Eastern Cooperative Oncology Group; LDH, Lactate dehydrogenase; IPI, International Prognostic Index; NCCN, 
National Comprehensive Cancer Network
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patients experienced CNS relapse within 1 and 2 years, 
respectively and the median time to CNS involvement 
was 10.4 months (range: 3.4–29.2). Among 581 patients 
excluding 16 patients having CNS involvement at 
diagnosis, 37 patients received prophylactic intrathecal 
MTX according to their physicians’ decision. Out of these 
37 patients, two patients with stage IV disease developed 
CNS relapse during the follow-up at 11 and 29 months 
after the diagnosis, respectively.
Risk factor analyses for CNS relapse
Among five IPI factors, Eastern Cooperative 
Oncology Group performance status (ECOG PS) ≥ 2, 
involvement of ≥ 2 extranodal sites, and elevation of 
serum LDH were associated with risk for CNS relapse 
in univariate analysis, whereas age > 60 (P = 0.241) and 
stage III/IV (P = 0.111) were not (Table 2). Patients with 
very high LDH [> ×3 upper limit of normal range (ULN), 
according to the NCCN-IPI] were strongly associated with 
the increased risk for CNS relapse (Figure 2A). However, 
enhanced analysis according to age failed to show 
difference, although very old age had a tendency of higher 
risk of CNS relapse (Figure 2B). Presence of B symptoms, 
and lower blood cell counts were associated with CNS 
relapse in univariate analysis (Table 2). Involvement of 
retroperitoneal lymph node, bone marrow (BM), sinonasal 
tract, nasopharynx, spleen, and testis were predictive of 
CNS relapse (Table 3). In contrast, patients with kidney 
or adrenal gland involvement (35/681= 6.0%; 3 patients 
had both kidney and adrenal gland involvement) were 
not associated with risk for CNS relapse. For multivariate 
analysis, we included LDH > ×3 ULN instead of > ×1 
ULN because of its stronger association with CNS 
relapse. Standard and NCCN-IPI were excluded from the 
multivariate analysis because they already comprised five 
individual factors. As a result, very high LDH, ECOG PS 
≥ 2, and involvement of testis and sinonasal tract, were 
independent factors for CNS relapse (Table 4). When 
we suppose that there are 3 risk factors for CNS relapse 
(taking testis and sinonasal tract involvement together), 
patients with more risk factors showed higher cumulative 
incidence of CNSrelapse, irrespective of higher vs. lower 
risk according to standard IPI (Figure 2C and 2D).
Outcomes of patients with CNS involvement
Five out of 14 patients who had CNS involvement at 
diagnosis, died due to systemic disease progression (n = 3), 
infectious complication (n = 1), and both (n = 1). Median 
follow-up duration for patients with CNS involvement 
at diagnosis was 38.2 months (95% CI, 24.8–51.7), and 
Kaplan-Meier curve for OS showed a plateau (Figure 3A). 
Among 26 patients with CNS relapse, 16 patients died 
Figure 1: CONSORT diagram of the current PROCESS study.
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due to systemic disease progression (n = 9) and infectious 
complication (n = 7). The OS of patients with CNS relapse 
was dismal (Figure 3B). Patients who underwent isolated 
CNS relapse showed superior OS compared to those who 
had synchronous CNS and systemic relapse [median OS 
38.2 months (95% CI, 26.7–49.6) vs. 13.7 months (95% 
CI, 9.5–17.9), P < 0.001; Figure 3C]. However, a majority 
of patients with isolated CNS relapse eventually died of 
progression of CNS or subsequent extra-CNS DLBCL, or 
infectious complication.
Table 2: Pretreatment clinical characteristics and central nervous system involvement
N = 581 Total number
CNS event
HR
Comparison of actuarial incidence
95% CI P
Sex Female 249 11 1
Male 332 15 1.04 0.48 2.27 0.919
Age ≤ 60 years 304 12 1
> 60 years 277 14 1.59 0.73 3.43 0.241
Age (enhanced) ≤ 40 years 70 2 1
41–60 years 234 10 1.55 0.34 7.07 0.573
61–75 years 208 9 1.86 0.40 8.62 0.427
> 75 years 69 5 3.90 0.75 20.18 0.105
ECOG PS 0/1 513 20 1
≥ 2 68 6 3.62 1.45 9.05 0.006
Stage I/II 294 10 1
III/IV 287 16 1.90 0.86 4.19 0.111
Extranodal sites 0/1 vs. 385 11 1
≥ 2 196 15 3.21 1.47 6.99 0.003
Serum LDH Normal 303 9 1
Increased 278 17 2.40 1.07 5.39 0.034
serum LDH (enhanced) ≤ ×1 ULN 303 9 1
×1–3 ULN 239 9 1.42 0.56 3.58 0.457
> ×3 ULN 39 8 11.83 4.51 31.10 < 0.001
serum LDH (modified) ≤ ×3 ULN 542 18 1
> ×3 ULN 39 8 10.50 4.53 24.31 < 0.001
standard IPI score < 3 380 10 1
≥ 3 201 16 3.90 1.76 8.56 0.001
NCCN-IPI score < 4 378 14 1
≥ 4 203 12 2.14 0.99 4.63 0.054
B symptoms Absence 440 16 1
Presence 141 10 2.25 1.02 4.95 0.045
Serum albumin > 3.5 g/dL 452 19 1
≤ 3.5 g/dL 129 7 1.62 0.68 3.86 0.276
Hemoglobin > 10 g/dL 500 20 1
≤ 10 g/dL 81 6 2.23 0.90 5.56 0.085
Platelet count > 100,000/mm3 548 21 1
≤ 100,000/mm3 33 5 5.60 2.10 14.88 0.001
Lymphocyte count > 1,000/mm3 444 16 1
≤ 1,000/mm3 137 10 2.27 1.03 5.00 0.042
CNS: central nervous system; HR: Hazard ratio; CI: confidence interval; ECOG- Eastern Cooperative Oncology Group; PS: 
performance status; LDH-Lactate dehydrogenase; IPI: International Prognostic Index
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Table 3: Relationship of pre-treatment nodal and extranodal involvement to central nervous 
system relapses among 581 patients
Nodal and extranodal involvement involvedpatients CNS event
Comparison of actuarial incidence
HR 95% CI P
Node region involvement
  Retroperitoneal 65 6 3.03 1.21 7.56 0.017
Extranodal involvement 
  Bone marrow 67 7 3.39 1.43 8.08 0.006
  Orbit 7 2 11.79 2.78 50.0 < 0.001
  Sinonasal tract 26 6 8.51 3.41 21.24 < 0.001
  Nasopharynx 48 6 3.39 1.36 8.45 0.009
  Liver 35 3 2.17 0.65 7.23 0.207
  Stomach 75 1 3.92 0.53 28.94 0.180
  Intestine 89 1 4.56 0.62 33.66 0.137
  Bone 64 5 2.23 0.84 5.92 0.107
  Spleen 83 7 2.59 1.10 6.17 0.032
  Kidney 19 2 3.02 0.71 12.80 0.133
  Testis 6 2 8.21 1.94 34.80 0.004
  Lung 37 2 1.43 0.34 6.07 0.625
  Breast 19 1 1.16 0.16 8.56 0.885
  Adrenal gland 19 1 1.55 0.21 11.42 0.669
CNS: central nervous system; HR: Hazard ratio; CI: confidence interval
Figure 2: (A–B) Cumulative risk of central nervous system relapse according to enhanced stratification of serum lactate 
dehydrogenase (LDH; A) and age (B); (C–D) Cumulative risk of central nervous system relapse according to the number of 
risk factors from the current study (very high LDH, the Eastern Cooperative Oncology Group performance status ≥ 2, and 
involvement of sinonasal tract or testis).
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DISCUSSION
Our study analyzed risk factors for CNS involvement 
in newly diagnosed DLBCL patients receiving R-CHOP 
who were registered the prospective cohort. Thus, we 
prospectively monitored the occurrence of CNS relapse 
in enrolled patients, and evaluated CNS involvement at 
diagnosis from patients at risk with CSF study and/or brain 
imaging. In this study, our patients who had a very high 
serum LDH, defined as > ×3 ULN, showed a remarkably 
higher risk for CNS relapse. It was in line with previous 
studies reporting its association with CNS relapses. Thus, 
the study analyzing 435 patients with DLBCL from 1999 
to 2005 and reporting 7.1% of CNS relapses showed that 
patients with a LDH > ×1 ULN did not have higher risk 
for CNS relapse among 309 patients treated with R-CHOP 
(P = 0.267) whereas patients with a LDH > ×2 ULN had 
a significant association (P = 0.026) [3, 15]. These results 
implied the simple dichotomization of patients according 
to usual cutoff value of LDH might not be suitable for 
predicting high risk group of DLBCL because serum LDH 
could reflect tumor burden and growth. Thus, patients with 
very high tumor burden as well as rapid growth of tumor 
cells might have more risk of treatment failure including 
CNS relapse, and those patients might have very high level 
of serum LDH. Therefore, higher level of serum LDH 
might be theoretically correlated with higher risk of CNS 
relapse because patients with high tumor burden could 
be more vulnerable to have CNS involvement. In our 
cohort, sinonasal tract and testis, traditional well-known 
risk factors for CNS relapse were associated with CNS 
relapse. On the other hand, the involvement of kidney 
or adrenal gland was not significantly related with CNS 
relapse unlike the study reporting CNS-IPI [13]. Similarly, 
our data showed that not all of five individual IPI factors 
had a statistically significant association with CNS relapse. 
Although these discrepancies between our data and that 
of German group study could be fully explained, it might 
be related with relatively smaller number of patients in 
our study (n = 581) than that of German group study 
(n = 2,741). Indeed, other variables of CNC-IPI such as 
age > 60 years and advanced stage showed higher hazard 
ratio (HR) than those of age ≤ 60 and Ann Arbor stage I/II 
(HR 1.59 and 1.90, respectively) although they were not 
statistically significant. Thus, age and stage might become 
significant factors for CNS involvement if the sample size 
could be expanded. 
Likewise, it was hard to predicate that patients with 
the involvement of those sites and other sites previously 
suggested for the site of high risk of CNS relapse were 
not associated with CNS relapse at all even though the 
involvement of sinonasal tract and testis were excluded 
in the CNS-IPI [13]. Extranodal involvement in the 
craniofacial area has been considered to increase the risk 
of CNS involvement because this area is anatomically 
close to skull base, which may allow lymphoma cells 
to contiguously invade the adjacent leptomeninges and 
brain [16]. Previous literatures as well as the experience 
from treating patients with acute lymphoblastic leukemia/
lymphoma have been supporting the association of 
testicular involvement with CNS relapse [6, 10, 12]. 
Therefore, it would be prudent and reasonable to still 
Table 4: Multivariate analysis of the risk of central nervous system involvement
Characteristics
Comparison of actuarial incidence
HR 95% CI P
ECOG PS ≥ 2 2.88 1.00 8.27 0.050
Extranodal sites ≥ 2 0.93 0.35 2.49 0.892
LDH > ×3 ULN 9.73 3.02 31.41 < 0.001
B symptom 1.23 0.44 3.49 0.694
Hemoglobin ≤ 10 g/dL 0.41 0.11 1.53 0.183
Platelet ≤ 100,000/mm3 1.97 0.57 6.76 0.283
Lymphocyte ≤ 1,000/mm3 1.42 0.54 3.75 0.483
Retroperitoneal lymph node 1.12 0.34 3.73 0.848
Bone marrow 1.37 0.47 3.99 0.560
Orbit 2.75 0.49 15.35 0.248
Sinonasal tract 12.87 3.57 46.42 < 0.001
Nasopharynx 2.16 0.70 6.66 0.182
Spleen 1.76 0.61 5.04 0.295
Testis 20.52 4.00 105.27 < 0.001
HR: Hazard ratio; CI: confidence interval; ECOG- Eastern Cooperative Oncology Group; PS: performance status; LDH-
Lactate dehydrogenase.
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suspect that patients with the involvement of those sites 
may have higher risk for CNS relapse. 
The comparison of OS according to CNS 
involvement showed that the OS of patients was 
significantly worse than that of patients without CNS 
involvement. These findings were consistent with the 
negative impact of CNS relapse on the prognosis of 
DLBCL patients. However, among 14 patients with 
CNS involvement at diagnosis, the OS showed a plateau. 
Although the number was too small and the types of CNS-
directed therapy were not uniform, this might be related 
with the introduction of CNS-directed therapy based on 
early identification of CNS involvement. Indeed, a previous 
study supported the usefulness of early intervention of 
CNS involvement in lymphoma patients because DLBCL 
patients with CNS involvement at diagnosis maintained 
their CR after they received MTX (8 g/m2) with leucovorin 
rescue every 2 weeks for 8 cycles, concurrently with 
R-CHOP every 3 weeks a total of 6 cycles with a median 
follow-up of 66 months [17]. Therefore, prognosis of 
patients with synchronous CNS and systemic DLBCL at 
diagnosis might not be as dismal as those with secondary 
CNS relapse and a part of patients could achieve long-term 
survival if they receive adequate CNS-directed therapy. 
Figure 3: Kaplan-Meier curves for overall survival of patients according to (A) central nervous system involvement 
(CNS) at diagnosis, (B) CNS involvement during or after immunochemotherapy, and (C) the pattern of CNS 
involvement during or after immunochemotherapy.
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Our study was a prospective cohort study focusing 
on the evaluation of CNS involvement including CNS 
relapse as well as CNS involvement at diagnosis, and 
it could be discriminated from the majority of studies 
reporting outcomes and risk factors because they were 
retrospective studies with relatively small number of 
patients and heterogeneous treatments and subtypes. 
Nevertheless, our study had several limitations. First, 
the diagnosis of leptomeningeal involvement was 
mainly based on conventional cytology and we did not 
perform flow cytometry to look for immunophenotypic 
evidence of CNS involvement. Given flow cytometric 
analysis would be more accurate for identifying patients 
with CNS involvement than conventional cytology 
[18], the use of standardized flow cytometric panels and 
uniform definitions of positivity might produce different 
results [19]. Second, we did not make obligation for 
CNS evaluation at diagnosis, prophylactic intrathecal 
chemotherapy, and type of CNS-directed therapy for 
patients with CNS involvement at diagnosis although 
we provided recommendations to each institute. 
Therefore, the incidence of CNS involvement at 
diagnosis might be slightly underestimated, and we 
could not analyze the role of intrathecal prophylaxis 
and efficacy of a certain CNS-directed therapy. Finally, 
we did not analyze the impact of novel morphological 
or biological classification of DLBCL to the incidence 
of CNS involvement, including germinal center B-cell 
(GCB) type DLBCL vs. non-GCB type [20], double hit 
or double protein DLBCL vs. not [21], and concordant 
vs. discordant BM involvement of DLBCL [22]. Future 
studies may define the relationship of the classifications 
to CNS involvement and provide more effective 
treatment strategy for patients with CNS involvement of 
DLBCL. 
In conclusion, very high serum LDH was an 
independent prognostic factor for CNS relapse in addition 
to ECOG PS ≥ 2 and involvement of sinonasal tract or 
testis in patients with DLBCL treated with R-CHOP. 
Future studies on the prognostic role of the enhanced 
stratification of previously known risk factors and the 
novel morphological or biological classifications of 
DLBCL for CNS relapse may contribute to define higher 
risk group for CNS relapse.
MATERIALS AND METHODS
Patients and study design
The inclusion criteria of our PROCESS (Prospective 
Cohort Study with Risk-Adapted Central Nervous System 
Evaluation in DLBCL) cohort were patients: (1) with 
newly diagnosed DLBCL according to the 2008 World 
Health Organization classification; (2) planned to receive 
R-CHOP as a primary treatment; (3) with ≥ 20 years of 
age; (4) with written informed consents. Patients with 
primary DLBCL of the CNS (PCNSL) were excluded. 
The diagnosis of CNS involvement was based on the 
presence of lymphoma cells in CSF cytology or brain 
parenchymal lesion on imaging studies. Incidence rate of 
CNS involvement at diagnosis and CNS relapse during or 
after R-CHOP chemotherapy were estimated, respectively. 
The actuarial incidence and analyses of CNS relapse was 
obtained after excluding patients with CNS involvement 
at diagnosis and then by censoring patients with follow-up 
loss or death before the occurrence of CNS involvement. 
The primary endpoint was incidence and risk factors for 
CNS relapse. The secondary endpoints were incidence 
of CNS involvement at diagnosis, OS, PFS, and time to 
CNS involvement. The OS was calculated from the time 
of diagnosis to the date of last follow-up or death from 
any cause whereas PFS was from the date of diagnosis to 
the date of relapse or progression or the last follow-up or 
death from any cause. The time to CNS involvement was 
from the date of diagnosis to the date of CNS relapse, and 
patients who were died from any cause before the CNS 
relapse occurred were censored. The study was approved 
by relevant institutional review boards of the participating 
institutes.
Study conduct
The study was conducted at 27 hospitals in Korea 
belonging to the Consortium for Improving Survival 
of Lymphoma (CISL) [23]. After enrollment, patients 
received 3-weekly R-CHOP up to 6–8 cycles. The cycle 
length could be shortened to 3–4 cycles in patients 
with stage I/II disease. Although CNS evaluation and 
prophylaxis were allowed based on each physician’s 
discretion, CNS evaluation via lumbar puncture was 
recommended if a patient had any symptom or sign 
suspicious for CNS involvement, or if a patient had at least 
one of the followings: (1) increased serum LDH; (2) ≥ 2 
extranodal involvement; (3) serum albumin < 3.5 g/dL; (4) 
BM involvement; (5) involvement of retroperitoneal lymph 
nodes; (6) involvement of testis, breast, bone, sinonasal 
tract, orbit, kidney/adrenal gland, or epidural spaces; or 
(7) with human immunodeficiency virus infection. Brain 
magnetic resonance imaging and/or CSF re-examination 
were recommended in case of abnormal results in CSF 
analysis such as pleocytosis despite negative cytology. For 
patients with CNS involvement at diagnosis, CNS-directed 
therapy such as intrathecal or intravenous methotrexate 
(MTX) was added to R-CHOP based on each institute’s 
policy. Intrathecal prophylaxis was allowed for those 
without CNS involvement at diagnosis but seem to be at 
risk of CNS relapse, based on each physician’s discretion. 
Once the occurrence of CNS involvement was found, it 
was recorded and regularly reported to the central office 
of the CISL. The follow-up data including survival and 




Fisher’s exact test was applied to identify associations 
between categorical variables. The time variable was 
estimated based on Kaplan-Meier curves and compared 
using the log-rank test. Following characteristics were 
evaluated as a potential risk factor for CNS relapse based 
on review of literature: five standard IPI factors [5, 7, 24], 
B symptom [7], involvement of retroperitoneal lymph 
node [11], kidney or adrenal gland [3], breast [9, 10], and 
testis [6, 10, 12]. Several extranodal sites of head or upper 
neck close to brain [orbit, sinonasal tract (nasal cavity and 
paranasal sinus), and nasopharynx], and sites of known 
poor prognostic implication (liver, spleen, bone, intestine, 
and lung) [14] were also evaluated. Serum albumin 
[11], anemia, thrombocytopenia, and lymphopenia were 
analyzed. Cox-regression hazard model was used for 
univariate and multivariate analysis. Variables with a P < 
0.1 in univariate analysis were included into the multivariate 
analysis. Two-sided P values < 0.05 were considered 
statistically significant using SPSS version 18.0 (Statistical 
Package for the Social Sciences Inc., Chicago, IL, U.S.A.).
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